AI-Enhanced Neurorehabilitation Exoskeleton Market Size, Share & Growth Analysis, 2026-2034

This report is updated with the latest market data and insights as of June 2026. Base year: 2025  |  Forecast period: 2026-2034

AI-Enhanced Neurorehabilitation Exoskeleton Market Size and Growth Outlook

The AI-Enhanced Neurorehabilitation Exoskeleton market size reached USD 1.52 billion globally in 2025, with a robust compound annual growth rate (CAGR) of 18.9% expected from 2026 to 2034. By 2034, the market is forecasted to attain a value of USD 7.38 billion, driven by surging demand for advanced rehabilitation technologies, rising incidence of neurological disorders, and continuous advancements in artificial intelligence integration. The rapid adoption of AI-powered exoskeletons in clinical and home care settings is catalyzing the transformation of neurorehabilitation paradigms, offering unprecedented patient outcomes and operational efficiencies.

Get Free Sample Report

The primary growth factor for the AI-Enhanced Neurorehabilitation Exoskeleton market lies in the escalating prevalence of neurological disorders such as stroke, spinal cord injuries, and traumatic brain injuries worldwide. According to the World Health Organization, strokes alone account for over 15 million cases annually, with a significant portion of survivors requiring long-term rehabilitation. Traditional rehabilitation methods often fall short in delivering consistent and intensive therapy, leading to suboptimal recovery. AI-enhanced exoskeletons bridge this gap by providing personalized, adaptive, and data-driven rehabilitation, which not only accelerates patient recovery but also improves overall functional outcomes. The integration of artificial intelligence allows these devices to analyze patient performance in real time, adjust therapy parameters, and offer predictive insights, thereby optimizing rehabilitation protocols for each individual. This positions robot-assisted neurorehabilitation as one of the most dynamic and clinically impactful growth areas in modern healthcare.

Another critical driver is the technological convergence of robotics, AI, and sensor technologies, which has transformed the landscape of neurorehabilitation. Modern exoskeletons are equipped with advanced sensors, machine learning algorithms, and cloud connectivity, enabling continuous monitoring and intelligent feedback. This technological leap has made exoskeletons more intuitive, safer, and capable of facilitating complex motor functions. As healthcare providers and rehabilitation centers seek to enhance patient engagement and reduce the burden on therapists, AI-powered exoskeletons are increasingly viewed as indispensable tools. Furthermore, favorable reimbursement policies in developed economies, coupled with growing awareness about the benefits of early and intensive neurorehabilitation, are fueling market expansion through 2034.

The surge in home-based rehabilitation is another significant growth catalyst for the AI-Enhanced Neurorehabilitation Exoskeleton market. The post-pandemic healthcare environment has firmly established the value of remote and decentralized care, highlighting the need for portable and user-friendly rehabilitation solutions. AI-enhanced exoskeletons designed for home use empower patients to continue therapy outside clinical environments, promoting independence and reducing healthcare costs. The proliferation of tele-rehabilitation platforms has further amplified this trend, and the rise of AI-enhanced remote physiotherapy solutions has created a complementary ecosystem in which exoskeleton therapy can be remotely supervised and adjusted by clinicians in real time. This shift is expected to persist well into 2034, driving sustained demand for innovative exoskeleton solutions tailored to home care settings.

AI in Rehabilitation Robotics is revolutionizing the way we approach patient recovery, particularly in the field of neurorehabilitation. By integrating artificial intelligence with advanced robotic systems, these technologies are capable of delivering highly personalized and adaptive therapy. This integration allows for the continuous monitoring of patient progress and the adjustment of therapy protocols in real time, ensuring that each session is optimized for the individual's specific needs. As a result, patients experience faster recovery times and improved functional outcomes, making AI in Rehabilitation Robotics an essential component of modern healthcare solutions.

From a regional perspective, North America currently dominates the AI-Enhanced Neurorehabilitation Exoskeleton market, accounting for the largest share in 2025, followed by Europe and the Asia Pacific. The region's leadership can be attributed to early technology adoption, robust healthcare infrastructure, and significant investments in research and development. Europe is also witnessing rapid uptake, supported by government initiatives to modernize rehabilitation services and a growing geriatric population. Meanwhile, the Asia Pacific region is emerging as a lucrative market, propelled by rising healthcare expenditure, increasing awareness about neurorehabilitation, and expanding access to advanced medical devices. Latin America and the Middle East & Africa, though currently representing smaller shares, are anticipated to experience accelerated growth as healthcare modernization efforts gain momentum across both regions.

AI-Enhanced Neurorehabilitation Exoskeleton Market by Product Type

The Product Type segment of the AI-Enhanced Neurorehabilitation Exoskeleton market is categorized into Lower Limb Exoskeletons, Upper Limb Exoskeletons, and Full Body Exoskeletons. Lower limb exoskeletons command the largest share at approximately 54.5% in 2025, primarily due to the high prevalence of mobility impairments resulting from conditions such as stroke and spinal cord injuries. These devices are extensively utilized in both acute and chronic rehabilitation, providing targeted assistance for walking, standing, and balance training. The integration of AI algorithms enables real-time gait analysis and adjustment, facilitating more effective neuroplasticity and functional recovery. Clinical studies have consistently demonstrated that AI-powered lower limb exoskeletons significantly enhance walking speed, endurance, and independence in patients, making them the preferred choice among healthcare providers globally.

Get Free Sample Report

Upper limb exoskeletons are gaining substantial traction, accounting for around 31% of the market in 2025, especially for patients recovering from strokes, traumatic brain injuries, or multiple sclerosis that predominantly affect arm and hand function. These devices leverage AI-driven adaptive control systems to deliver precise, patient-specific therapy, enabling the repetitive and intensive movement training essential for motor relearning. The demand for upper limb exoskeletons is further bolstered by the growing emphasis on activities of daily living (ADL) rehabilitation, as regaining arm and hand function is critical for independence. The broader category of exoskeletons for upper limb rehabilitation is evolving rapidly, with recent advancements in lightweight materials, ergonomic design, and intuitive human-machine interfaces making these devices more accessible and comfortable for prolonged use in both clinical and home settings.

Full body exoskeletons, while representing approximately 14.5% of the market in 2025, are witnessing rapid innovation and adoption. These systems provide comprehensive support for both upper and lower limbs, making them suitable for patients with extensive neurological impairments or those requiring holistic rehabilitation. AI-enhanced full body exoskeletons can synchronize complex multi-joint movements, offering a more natural and coordinated therapy experience. Although their higher cost and complexity have limited widespread deployment to date, ongoing research and development efforts are focused on improving affordability, portability, and user-friendliness. As these challenges are addressed through 2034, the full body exoskeleton segment is expected to register significant growth, particularly in specialized rehabilitation centers and advanced hospitals.

The competitive landscape within the product type segment is marked by continuous innovation, with leading manufacturers investing heavily in R&D to enhance the functionality, safety, and adaptability of their exoskeletons. Partnerships with academic institutions and healthcare providers are common, aimed at validating clinical efficacy and expanding the range of indications. As the market matures, differentiation is increasingly driven by the integration of advanced AI features such as predictive analytics, automated progress tracking, and personalized therapy recommendations. This trend is expected to intensify competition and accelerate the adoption of AI-enhanced exoskeletons across all product categories through 2034.

AI-Enhanced Neurorehabilitation Exoskeleton Market Report Scope

AI-Enhanced Neurorehabilitation Exoskeleton Market by Application

The Application segment of the AI-Enhanced Neurorehabilitation Exoskeleton market encompasses Stroke Rehabilitation, Spinal Cord Injury, Traumatic Brain Injury, Multiple Sclerosis, and Others. Stroke rehabilitation remains the dominant application, accounting for the largest market share in 2025. The high incidence of stroke, coupled with the critical need for intensive and early intervention, drives demand for advanced rehabilitation solutions. AI-powered exoskeletons offer a transformative approach by enabling repetitive, high-intensity training that promotes neuroplasticity and functional recovery. Real-time data analytics and adaptive therapy protocols further enhance outcomes, reducing the risk of long-term disability and improving quality of life for stroke survivors globally.

Spinal cord injury rehabilitation represents another significant application area, with AI-enhanced exoskeletons enabling individuals with partial or complete paralysis to regain mobility and independence. These devices provide targeted assistance for walking and standing, while AI algorithms continuously adapt to patient progress and physiological feedback. Clinical evidence suggests that exoskeleton-assisted therapy can improve muscle strength, cardiovascular health, and psychological well-being in spinal cord injury patients. The growing availability of exoskeletons in rehabilitation centers, combined with increasing insurance coverage in major markets, is expected to propel further growth in this segment through 2034.

Traumatic brain injury (TBI) and multiple sclerosis (MS) are also key application areas driving the adoption of AI-powered neurorehabilitation exoskeletons. TBI patients often require personalized rehabilitation to address complex motor and cognitive deficits. AI-enhanced exoskeletons facilitate customized therapy regimens, monitor cognitive load, and provide motivational feedback, thereby supporting comprehensive recovery. In the case of MS, where disease progression can lead to varying degrees of mobility impairment, exoskeletons offer adaptable support tailored to individual needs. The ability to adjust therapy intensity and duration based on real-time patient data is a critical advantage, enabling more responsive and effective rehabilitation for this population.

The "Others" category includes applications such as cerebral palsy, Parkinson's disease, and orthopedic rehabilitation, reflecting the expanding scope of AI-enhanced exoskeletons. As clinical evidence accumulates and technology becomes more accessible through 2034, new indications are continually being explored. This diversification is expected to broaden the market's addressable base and drive sustained growth across multiple patient populations. The expanding landscape of neurorehabilitation devices as a whole is creating complementary demand that reinforces the adoption of AI-enhanced exoskeletons across these emerging application categories.

AI-Enhanced Neurorehabilitation Exoskeleton Market by End-User

The End-User segment of the AI-Enhanced Neurorehabilitation Exoskeleton market is divided into Hospitals & Clinics, Rehabilitation Centers, Home Care Settings, and Others. Hospitals and clinics constitute the largest end-user segment, accounting for a significant share of market revenue in 2025. These facilities are typically the first adopters of advanced medical technologies, driven by the need to deliver high-quality, evidence-based care. The integration of AI-enhanced exoskeletons into hospital rehabilitation programs has improved patient throughput, reduced therapy costs, and enhanced clinical outcomes. Hospitals also benefit from comprehensive training and support provided by manufacturers, ensuring optimal utilization and patient safety across diverse clinical settings.

Rehabilitation centers represent a rapidly growing end-user segment, as these specialized facilities are dedicated to delivering intensive, multidisciplinary therapy for patients with complex neurological conditions. The adoption of AI-powered exoskeletons in rehabilitation centers is driven by their ability to provide high-frequency, repetitive training that accelerates functional recovery. These centers often serve as hubs for clinical research and innovation, collaborating with technology developers to refine and validate new exoskeleton applications. The presence of skilled therapists and multidisciplinary teams further enhances the effectiveness of AI-driven rehabilitation protocols, positioning rehabilitation centers as critical drivers of market growth through 2034.

Home care settings are emerging as a vital end-user segment, reflecting the broader trend towards decentralized and patient-centered care. AI-enhanced exoskeletons designed for home use empower patients to continue therapy independently, reducing the need for frequent hospital visits and lowering overall healthcare costs. The integration of tele-rehabilitation platforms and remote monitoring capabilities enables clinicians to track patient progress, adjust therapy plans, and provide timely support from any location. This shift is particularly beneficial for patients in rural or underserved areas, where access to specialized rehabilitation services may be limited. The convenience and flexibility of home-based exoskeletons are expected to drive substantial market growth through the 2026-2034 forecast period.

The "Others" category includes long-term care facilities, research institutions, and military rehabilitation programs. These settings are increasingly adopting AI-enhanced exoskeletons for specialized applications, such as supporting veterans with traumatic injuries or conducting advanced clinical research. The expanding diversity of end-users underscores the versatility and transformative potential of AI-powered neurorehabilitation exoskeletons across the full continuum of care.

AI-Enhanced Neurorehabilitation Exoskeleton Market by Mobility Type

The Mobility Type segment is bifurcated into Mobile and Stationary exoskeletons, each catering to distinct rehabilitation needs and environments. Mobile exoskeletons, designed for dynamic movement and ambulation, dominate the market due to their versatility and broad applicability. These devices are equipped with advanced AI algorithms that enable real-time adaptation to changing terrains, user intent, and physiological feedback. Mobile exoskeletons are particularly valuable for gait training, community reintegration, and promoting independence in patients with mobility impairments. Their portability and ease of use make them suitable for both clinical and home-based rehabilitation, driving widespread adoption through the forecast period. Developments in areas such as the robotic rehabilitation ankle exosuit segment illustrate how mobile, targeted devices are becoming increasingly refined, offering precise joint-level support that complements broader exoskeleton systems.

Stationary exoskeletons, while representing a smaller market share, play a critical role in early-stage rehabilitation and intensive therapy settings. These devices are typically used in hospitals and rehabilitation centers, where patients may require substantial support and safety during initial recovery phases. AI-powered stationary exoskeletons offer precise control over movement parameters, facilitating targeted therapy for specific muscle groups or joints. They are often integrated with virtual reality and biofeedback systems to enhance patient engagement and motivation. The stability and controlled environment provided by stationary exoskeletons are essential for patients with severe impairments or those at high risk of falls.

The choice between mobile and stationary exoskeletons is influenced by factors such as patient condition, therapy goals, and care setting. Mobile exoskeletons are preferred for community-based and home care applications, while stationary devices are favored in acute and sub-acute rehabilitation environments. As technology advances through 2034, the distinction between these categories is blurring, with hybrid solutions emerging that combine the benefits of both mobility types. Manufacturers are increasingly focusing on modular designs that allow for seamless transitions between stationary and mobile modes, enhancing flexibility and patient outcomes across diverse rehabilitation contexts.

The mobility type segment is characterized by rapid innovation and evolving user preferences. AI integration continues to enhance the functionality and adaptability of both mobile and stationary exoskeletons, enabling more personalized and effective rehabilitation. As patient expectations and clinical standards evolve, the demand for versatile, user-friendly, and intelligent exoskeleton solutions is expected to remain strong, driving sustained growth across both mobility categories through 2034.

AI-Enhanced Neurorehabilitation Exoskeleton Market by Technology

The Technology segment of the AI-Enhanced Neurorehabilitation Exoskeleton market comprises Powered, Passive, and Hybrid exoskeletons. Powered exoskeletons dominate the market, accounting for the majority of revenue in 2025, due to their advanced capabilities and widespread clinical adoption. These devices utilize electric motors, actuators, and AI-driven control systems to provide active assistance and resistance during therapy. Powered exoskeletons are highly effective in facilitating complex movements, compensating for muscle weakness, and enabling intensive, repetitive training. The integration of AI enhances their adaptability, allowing for real-time adjustments based on patient performance, fatigue, and recovery progress, reinforcing their status as the technology of choice for intensive neurorehabilitation.

Passive exoskeletons, which rely on mechanical structures and springs rather than powered actuators, represent a smaller but growing market segment. These devices are typically used for less intensive rehabilitation or as assistive devices for activities of daily living. Passive exoskeletons offer advantages such as simplicity, lower cost, and reduced maintenance requirements. While they lack the advanced features of powered systems, ongoing research is exploring the integration of AI-based analytics and feedback mechanisms to enhance their therapeutic value. Passive exoskeletons are particularly suited for patients with mild impairments or those in the later stages of recovery, where targeted, low-intensity support is sufficient for continued progress.

Hybrid exoskeletons combine elements of both powered and passive technologies, offering a balance between functionality, affordability, and user comfort. These devices can switch between active and passive modes based on therapy requirements and patient needs. AI algorithms play a crucial role in determining the optimal mode of operation, ensuring that therapy is both effective and energy-efficient. Hybrid exoskeletons are gaining popularity in rehabilitation centers and home care settings, where flexibility and adaptability are highly valued. The ability to customize therapy intensity and support levels makes hybrid exoskeletons suitable for a wide range of patients and indications, and this segment is expected to register the fastest growth rate within the technology category through 2034.

The technology segment is a focal point for innovation and differentiation in the AI-Enhanced Neurorehabilitation Exoskeleton market. Leading manufacturers are investing in the development of next-generation powered and hybrid exoskeletons with enhanced AI capabilities, such as machine learning-based movement prediction, automated progress tracking, and cloud-based data analytics. As the technology matures and becomes more cost-effective, broader adoption across diverse care settings and patient populations is anticipated throughout the 2026-2034 forecast horizon.

AI-Enhanced Neurorehabilitation Exoskeleton Market Opportunities and Threats

The AI-Enhanced Neurorehabilitation Exoskeleton market presents significant opportunities for growth and innovation. One of the most promising opportunities lies in the expansion of home-based rehabilitation and tele-rehabilitation services. As healthcare systems worldwide shift towards decentralized and patient-centered care models, the demand for portable, user-friendly exoskeletons is surging. AI-powered devices that enable remote monitoring, real-time data analytics, and personalized therapy plans are ideally positioned to meet this demand. Additionally, partnerships between technology developers, healthcare providers, and insurance companies can facilitate broader access to advanced rehabilitation solutions, driving market penetration in both developed and emerging economies through 2034.

Another key opportunity is the ongoing integration of advanced AI technologies, such as deep learning, computer vision, and natural language processing, into neurorehabilitation exoskeletons. These innovations have the potential to further enhance device intelligence, autonomy, and adaptability, enabling more precise and effective therapy. The development of interoperable platforms that connect exoskeletons with electronic health records, wearable sensors, and telemedicine systems can create a seamless continuum of care, improving patient outcomes and operational efficiency. Furthermore, expanding the range of clinical indications, such as pediatric rehabilitation and post-orthopedic surgery recovery, can open new revenue streams and broaden the market's addressable base. The growing body of research supporting exo-suit assisted stroke upper-limb rehabilitation illustrates how targeted innovation in specific indications is creating measurable clinical and commercial value.

Despite these opportunities, the market faces several restraining factors that could impede growth. The high cost of AI-enhanced exoskeletons remains a significant barrier, particularly in price-sensitive markets and low-resource settings. Limited reimbursement coverage for advanced rehabilitation technologies can also deter adoption, especially among smaller healthcare providers and individual patients. Technical challenges, such as ensuring device safety, reliability, and user comfort across diverse patient populations, must be addressed to gain widespread acceptance. Additionally, regulatory hurdles and lengthy approval processes can delay market entry for new products. Overcoming these challenges will require collaborative efforts among manufacturers, policymakers, and healthcare stakeholders to ensure that the benefits of AI-powered neurorehabilitation are accessible to all who need them throughout the forecast period.

AI-Enhanced Neurorehabilitation Exoskeleton Market Size by Region

From a regional perspective, North America leads the AI-Enhanced Neurorehabilitation Exoskeleton market, accounting for approximately 40.5% of the global market size in 2025, equivalent to roughly USD 616 million. The region's dominance is underpinned by a strong healthcare infrastructure, early adoption of advanced technologies, and significant investments in research and development. The presence of leading market players, favorable reimbursement policies, and a high prevalence of neurological disorders further contribute to North America's leadership position. The United States, in particular, is at the forefront of innovation, with numerous clinical trials, academic collaborations, and commercialization initiatives driving market growth throughout the 2026-2034 forecast period.

Get Free Sample Report

Europe is the second-largest regional market, holding a share of approximately 28.5% in 2025, or roughly USD 433 million. The region benefits from robust government support for healthcare modernization, a growing geriatric population, and increasing awareness about the benefits of early and intensive neurorehabilitation. Countries such as Germany, the United Kingdom, and France are key contributors, with active research communities and progressive healthcare policies. Europe is also witnessing a surge in public-private partnerships aimed at expanding access to AI-powered exoskeletons and integrating them into national rehabilitation programs. The region is expected to maintain a healthy CAGR of approximately 18.2% through 2034, driven by ongoing innovation and expanding clinical applications across the continent.

The Asia Pacific region is emerging as a high-growth market, with a current share of approximately 19% or roughly USD 289 million in 2025. Rapid economic development, rising healthcare expenditure, and a growing burden of neurological disorders are fueling demand for advanced rehabilitation technologies. Countries such as China, Japan, and South Korea are leading the way, supported by government initiatives to improve healthcare infrastructure and promote medical innovation. The Asia Pacific market is expected to register the fastest CAGR of approximately 20.8% over the 2026-2034 forecast period, as increasing awareness and expanding access to care drive adoption. Latin America and the Middle East & Africa, while currently representing smaller market shares of approximately 6.5% and 5.5% respectively, are anticipated to experience accelerated growth as healthcare modernization efforts gain momentum and barriers to adoption are gradually overcome in both regions.

AI-Enhanced Neurorehabilitation Exoskeleton Market Competitive Landscape

The competitive landscape of the AI-Enhanced Neurorehabilitation Exoskeleton market is characterized by intense innovation, strategic partnerships, and a growing focus on clinical validation. Leading manufacturers are investing heavily in research and development to enhance the functionality, safety, and user experience of their exoskeletons. The integration of advanced AI capabilities, such as machine learning-based movement prediction, automated progress tracking, and cloud-based analytics, is a key differentiator in the market. Companies are also prioritizing interoperability, ensuring that their devices can seamlessly connect with electronic health records, wearable sensors, and tele-rehabilitation platforms. As the market matures through 2034, competition is shifting towards value-added services such as comprehensive training, remote support, and data-driven therapy optimization.

Strategic collaborations and partnerships are playing a pivotal role in shaping the competitive landscape. Manufacturers are increasingly partnering with academic institutions, healthcare providers, and technology companies to accelerate product development, validate clinical efficacy, and expand the range of indications. These collaborations enable the rapid translation of research findings into commercial products and facilitate access to new markets globally. In addition, partnerships with insurance companies and government agencies are helping to overcome reimbursement challenges and broaden access to advanced rehabilitation solutions. The competitive environment is further intensified by the entry of new players, including well-funded startups and established technology corporations, who are leveraging their expertise in AI, robotics, and data analytics to disrupt traditional rehabilitation paradigms.

The market is also witnessing a trend towards consolidation, as larger players acquire innovative startups to expand their product portfolios and accelerate time-to-market. This consolidation is expected to enhance the overall competitiveness of the industry, drive economies of scale, and facilitate the development of next-generation exoskeletons with enhanced AI capabilities through 2034. However, the market remains highly dynamic, with continuous innovation and evolving user preferences shaping the competitive landscape. Companies that can effectively combine technological excellence, clinical validation, and user-centric design are likely to emerge as leaders in the AI-Enhanced Neurorehabilitation Exoskeleton market over the forecast horizon.

Major companies operating in the market include ReWalk Robotics, Ekso Bionics, Cyberdyne Inc., Rex Bionics, Hocoma AG (DIH Medical), Bionik Laboratories, Ottobock SE & Co. KGaA, ExoAtlet, Fourier Intelligence, Myomo Inc., Wandercraft, Tyromotion GmbH, Gogoa Mobility Robots, Parker Hannifin Corporation, Wearable Robotics Srl, Technaid S.L., and Honda Motor Co., Ltd. ReWalk Robotics is renowned for its advanced lower limb exoskeletons, widely used in spinal cord injury rehabilitation. Ekso Bionics offers a comprehensive portfolio of exoskeletons for both lower and upper limb rehabilitation, with a strong focus on AI-driven adaptive control systems. Cyberdyne Inc., based in Japan, is a pioneer in the development of hybrid assistive limb (HAL) technology, integrating robotics and AI for a wide range of neurological conditions. Rex Bionics specializes in full body exoskeletons, providing comprehensive support for patients with severe mobility impairments across multiple clinical settings.

Hocoma AG, a subsidiary of DIH Medical, is a global leader in robotic rehabilitation solutions, offering a range of AI-powered exoskeletons and therapy devices. Bionik Laboratories focuses on upper limb exoskeletons, leveraging AI and sensor technologies to deliver personalized therapy for stroke and TBI patients. Ottobock SE & Co. KGaA, a major force in the global medical device industry, has expanded its rehabilitation robotics portfolio through strategic acquisitions and in-house innovation. ExoAtlet and Fourier Intelligence are prominent players from Asia, rapidly expanding their international footprint through innovative product offerings and strategic partnerships. Myomo Inc. and Wandercraft bring specialized expertise in powered orthotics and ambulatory exoskeletons respectively, each contributing to the market's continued evolution. These companies are at the forefront of technological innovation, clinical validation, and market expansion, driving the evolution of the AI-Enhanced Neurorehabilitation Exoskeleton market through 2034.

Top Companies in the AI-Enhanced Neurorehabilitation Exoskeleton Market

• Ekso Bionics
• ReWalk Robotics
• Cyberdyne Inc.
• Hocoma AG (DIH Medical)
• Bionik Laboratories
• Parker Hannifin Corporation
• Fourier Intelligence
• Myomo Inc.
• Rex Bionics
• Wandercraft
• Gogoa Mobility Robots
• Ottobock SE & Co. KGaA
• ExoAtlet
• Tyromotion GmbH
• Wearable Robotics Srl
• Technaid S.L.
• Honda Motor Co., Ltd.